Page 1

August 11 , 2021 ADMA BIOLOGICS ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments Achieved Record Total Revenues of $ 17.8 Million in Second Quarter 2021 , a 129 % Increase Over Second Quarter 2020 Narrowed Gross and Net Losses Year - over - year ADMA Now Anticipates Exiting 2021 Approaching an Annualized Revenue Run Rate of Approximately $ 100 Million or More ; Reiterates All Previously Communicated Strategic and Financial Objectives Management to Host Conference Call and Webcast Today at 4:30 p.m. ET RAMSEY , N.J. and BOCA RATON , Fla . , Aug. 11 , 2021 ( GLOBE NEWSWIRE ) -- ADMA Biologics , Inc. ( Nasdaq : ADMA ) ( " ADMA " or the " Company " ) , an end - to - end commercial biopharmaceutical company dedicated to manufacturing , marketing and developing specialty plasma - derived biologics , today reported financial results for the three months ended June 30 , 2021 , its fiscal second quarter , and provided an overview of recent progress and accomplishments . " ADMA continues to achieve milestones and execute on its commercial and operational strategies as evidenced by the strong second quarter financial results and regulatory successes . The totality of the year - to - date accomplishments across business segments has the Company well - positioned to sustain quarter - over - quarter revenue growth with improving margins for the foreseeable future , " said Adam Grossman , President and Chief Executive Officer of ADMA . " Less than two years into ADMA's commercial launch of its intravenous immune globulin ( " IVIG " ) product portfolio , the Company generated record quarterly revenues of $ 17.8 million , representing an increase of 129 % year - over - year . This top - line growth is particularly impressive in light of the pandemic - related headwinds that continue to persist throughout the product launch period , which impacted industry supply chains and limited engagement with physicians and providers . Additionally , these results do not reflect the substantial benefits anticipated from the recently approved BIVIGAMⓇ expanded production scale , increasing our facility's total annual peak production capacity from 400,000 liters to 600,000 liters , as well as the expected approval of the VanRx SA25 Workcell aseptic fill - finish machine ( " VanRx " ) in the second half of 2021. We are confident that our underlying business trends have demonstrated strength and resilience year - to - date and can continue improving in the second half of 2021 and beyond as operating efficiencies materialize and production ramp-